Ng 2001

1 Treatments

**Studied treatment**  metformin 500 mg TID

**Control treatment**  placebo

**Concomittant treatments**  -

Women (%)  -

Age (mean), years  -

2 Patients

**Patients**  PCO

Inclusion criteria  -

Exclusion criteria  -

Weight (kg)  -

Body-mass index (kg/m^2)  -

Waist circumference (cm)  -

obesity  -

Family history of diabetes mellitus (%)  -

Definitions of impaired glucose tolerance and type 2 diabetes  -

3 Methods

**Blinding**  -

**Design**  -

**Centers**  -

**Geographical area**  -

**Sizes**  10/10

**fasting plasma glucose (mmol/L)**  -
2-h plasma glucose (mmol/L) -

Dyslipidaemia -

2hPG (>9.4–11.0 mmol/L) -

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>hospitalization for heart failure</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death, MI, stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>diabetes</td>
<td>-10</td>
<td>-10</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal MI</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>normoglycemia</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovasculaire events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References

Ng EH, Wat NM, Ho PC Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001;16:1625-31 [11473953]